Maxim Group analyst Jason McCarthy assigned a Buy rating to AIM ImmunoTech (AIM) yesterday and set a price target of $5.00. The company’s shares closed last Thursday at $2.06.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 28.7% and a 50.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AIM ImmunoTech with a $5.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.11 and a one-year low of $0.38. Currently, AIM ImmunoTech has an average volume of 5.06M.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
